These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 29397435)

  • 21. Graves' orbitopathy, idiopathic orbital inflammatory pseudotumor and Epstein-Barr virus infection: a serological and molecular study.
    Leo M; Maggi F; Dottore GR; Casini G; Mazzetti P; Pistello M; Sellari-Franceschini S; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2017 May; 40(5):499-503. PubMed ID: 27987077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD8+CD28-lymphocytes in peripheral blood and serum concentrations of soluble interleukin 6 receptor are increased in patients with Graves' orbitopathy and correlate with disease activity.
    Slowik M; Urbaniak-Kujda D; Bohdanowicz-Pawlak A; Kapelko-Slowik K; Dybko J; Wolowiec D; Jazwiec B; Daroszewski J
    Endocr Res; 2012; 37(2):89-95. PubMed ID: 22489922
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifibrotic effects of quercetin in primary orbital fibroblasts and orbital fat tissue cultures of Graves' orbitopathy.
    Yoon JS; Chae MK; Jang SY; Lee SY; Lee EJ
    Invest Ophthalmol Vis Sci; 2012 Aug; 53(9):5921-9. PubMed ID: 22871832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
    Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
    Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum antibodies to collagen XIII: a further good marker of active Graves' ophthalmopathy.
    De Bellis A; Sansone D; Coronella C; Conte M; Iorio S; Perrino S; Battaglia M; Bellastella G; Wall JR; Bellastella A; Bizzarro A
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):24-9. PubMed ID: 15638866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Th1/Th2 cytokines in patients with Graves' disease with or without ophthalmopathy.
    Esfahanian F; Naimi E; Doroodgar F; Jadali Z
    Iran J Allergy Asthma Immunol; 2013 May; 12(2):168-75. PubMed ID: 23754356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
    Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
    PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical studies using immunized Guinea pig sera with features of anti-human thyroid, eye and skeletal antibody and Graves' sera.
    Molnár I; Szombathy Z; Kovács I; Szentmiklósi AJ
    J Clin Immunol; 2007 Mar; 27(2):172-80. PubMed ID: 17243008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alterations in the intestinal microbiota of patients with severe and active Graves' orbitopathy: a cross-sectional study.
    Shi TT; Xin Z; Hua L; Zhao RX; Yang YL; Wang H; Zhang S; Liu W; Xie RR
    J Endocrinol Invest; 2019 Aug; 42(8):967-978. PubMed ID: 30674011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of advanced glycation end-products and antibodies against them (anti-CML and anti-CEL) in the serum of Graves' orbitopathy patients before and after methylprednisolone treatment.
    Strzelczyk J; Szumska M; Damasiewicz-Bodzek A; Krywult A; Długaszek M; Czubilińska J; Gawlik K; Synowiec K; Tyrpień-Golder K; Poczkaj K; Kos-Kudła B
    Endokrynol Pol; 2016; 67(4):383-9. PubMed ID: 27387241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transforming growth factor β1 (TGFβ1) and vascular endothelial growth factor (VEGF) in the blood of healthy people and patients with Graves' orbitopathy--a new mechanism of glucocorticoids action?
    Kajdaniuk D; Marek B; Niedziołka-Zielonka D; Foltyn W; Nowak M; Siemińska L; Borgiel-Marek H; Głogowska-Szeląg J; Ostrowska Z; Drożdż L; Kos-Kudła B
    Endokrynol Pol; 2014; 65(5):348-56. PubMed ID: 25301484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score.
    Choi W; Li Y; Ji YS; Yoon KC
    BMC Ophthalmol; 2018 Nov; 18(1):303. PubMed ID: 30463536
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between serum cholesterol and Graves' orbitopathy (GO): a confirmatory study.
    Lanzolla G; Sabini E; Profilo MA; Mazzi B; Sframeli A; Rocchi R; Menconi F; Leo M; Nardi M; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2018 Dec; 41(12):1417-1423. PubMed ID: 29923059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxidative stress and antioxidant activity in orbital fibroadipose tissue in Graves' ophthalmopathy.
    Hondur A; Konuk O; Dincel AS; Bilgihan A; Unal M; Hasanreisoglu B
    Curr Eye Res; 2008 May; 33(5):421-7. PubMed ID: 18568878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Orbital Fibroblasts From Graves' Orbitopathy Patients Share Functional and Immunophenotypic Properties With Mesenchymal Stem/Stromal Cells.
    Brandau S; Bruderek K; Hestermann K; Görtz GE; Horstmann M; Mattheis S; Lang S; Eckstein A; Berchner-Pfannschmidt U
    Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6549-57. PubMed ID: 26457540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression and clinical significance of connective tissue growth factor (CTGF) in Graves' ophthalmopathy.
    Huang YM; Chang PC; Wu SB; Kau HC; Tsai CC; Liu CJ; Wei YH
    Br J Ophthalmol; 2017 May; 101(5):676-680. PubMed ID: 27543288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PDGF enhances orbital fibroblast responses to TSHR stimulating autoantibodies in Graves' ophthalmopathy patients.
    van Steensel L; Hooijkaas H; Paridaens D; van den Bosch WA; Kuijpers RW; Drexhage HA; van Hagen PM; Dik WA
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E944-53. PubMed ID: 22438231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathophysiology of Graves' ophthalmopathy.
    Stiebel-Kalish H; Robenshtok E; Gaton DD
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():178-81. PubMed ID: 20467359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current perspectives on the role of orbital fibroblasts in the pathogenesis of Graves' ophthalmopathy.
    Dik WA; Virakul S; van Steensel L
    Exp Eye Res; 2016 Jan; 142():83-91. PubMed ID: 26675405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.